Nourhan M. Elsoudy , Maha Anwar , Hanan Hussien , Hossam Mahmoud Yassien , Lamiaa Mahmoud Abdelazeez
{"title":"一些生理和技术因素对18F-FDG在PET/CT上有效剂量估计的影响","authors":"Nourhan M. Elsoudy , Maha Anwar , Hanan Hussien , Hossam Mahmoud Yassien , Lamiaa Mahmoud Abdelazeez","doi":"10.1016/j.radphyschem.2024.112438","DOIUrl":null,"url":null,"abstract":"<div><div>Whole-body fluorodeoxyglucose F18 (<sup>18</sup>F-FDG) is the most common radiopharmaceutical use in PET/CT imaging for cancer staging. Although radiopharmaceutical for PET/CT examination has been acknowledged for its safety and efficacy, the internal dosimetry and effective dose (ED) from the examinations are rarely discussed. Hence, this study aimed to evaluate radiation ED and influencing factors of <sup>18</sup>F-FDG PET/CT in breast cancer and lymphoma patients. The findings contribute to refining imaging protocols, optimizing radiation exposure, and enhancing the clinical utility of PET/CT in cancer diagnostics and monitoring. Significant correlations were observed between PET effective dose and physiological factors such as age, weight, blood glucose level (BLG), and injected dose, particularly in NHL patients, with a strong negative correlation between PET effective dose and tumor-to-liver ratio (TLR). Based on our results, we recommend excluding patients with blood glucose levels below 80 mg/dL from PET/CT protocols. Additionally, to minimize CT effective doses and adhere to the ALARA principle, reducing tube-current modulation is advised, as it significantly impacts DLP values and the overall effective dose in PET/CT procedures.</div></div>","PeriodicalId":20861,"journal":{"name":"Radiation Physics and Chemistry","volume":"229 ","pages":"Article 112438"},"PeriodicalIF":2.8000,"publicationDate":"2024-11-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Effect of some physiological and technical factors on Effective Dose Estimation of Patients Administered with 18F-FDG in PET/CT\",\"authors\":\"Nourhan M. Elsoudy , Maha Anwar , Hanan Hussien , Hossam Mahmoud Yassien , Lamiaa Mahmoud Abdelazeez\",\"doi\":\"10.1016/j.radphyschem.2024.112438\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><div>Whole-body fluorodeoxyglucose F18 (<sup>18</sup>F-FDG) is the most common radiopharmaceutical use in PET/CT imaging for cancer staging. Although radiopharmaceutical for PET/CT examination has been acknowledged for its safety and efficacy, the internal dosimetry and effective dose (ED) from the examinations are rarely discussed. Hence, this study aimed to evaluate radiation ED and influencing factors of <sup>18</sup>F-FDG PET/CT in breast cancer and lymphoma patients. The findings contribute to refining imaging protocols, optimizing radiation exposure, and enhancing the clinical utility of PET/CT in cancer diagnostics and monitoring. Significant correlations were observed between PET effective dose and physiological factors such as age, weight, blood glucose level (BLG), and injected dose, particularly in NHL patients, with a strong negative correlation between PET effective dose and tumor-to-liver ratio (TLR). Based on our results, we recommend excluding patients with blood glucose levels below 80 mg/dL from PET/CT protocols. Additionally, to minimize CT effective doses and adhere to the ALARA principle, reducing tube-current modulation is advised, as it significantly impacts DLP values and the overall effective dose in PET/CT procedures.</div></div>\",\"PeriodicalId\":20861,\"journal\":{\"name\":\"Radiation Physics and Chemistry\",\"volume\":\"229 \",\"pages\":\"Article 112438\"},\"PeriodicalIF\":2.8000,\"publicationDate\":\"2024-11-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Radiation Physics and Chemistry\",\"FirstCategoryId\":\"92\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0969806X24009307\",\"RegionNum\":3,\"RegionCategory\":\"物理与天体物理\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"CHEMISTRY, PHYSICAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Radiation Physics and Chemistry","FirstCategoryId":"92","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0969806X24009307","RegionNum":3,"RegionCategory":"物理与天体物理","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"CHEMISTRY, PHYSICAL","Score":null,"Total":0}
Effect of some physiological and technical factors on Effective Dose Estimation of Patients Administered with 18F-FDG in PET/CT
Whole-body fluorodeoxyglucose F18 (18F-FDG) is the most common radiopharmaceutical use in PET/CT imaging for cancer staging. Although radiopharmaceutical for PET/CT examination has been acknowledged for its safety and efficacy, the internal dosimetry and effective dose (ED) from the examinations are rarely discussed. Hence, this study aimed to evaluate radiation ED and influencing factors of 18F-FDG PET/CT in breast cancer and lymphoma patients. The findings contribute to refining imaging protocols, optimizing radiation exposure, and enhancing the clinical utility of PET/CT in cancer diagnostics and monitoring. Significant correlations were observed between PET effective dose and physiological factors such as age, weight, blood glucose level (BLG), and injected dose, particularly in NHL patients, with a strong negative correlation between PET effective dose and tumor-to-liver ratio (TLR). Based on our results, we recommend excluding patients with blood glucose levels below 80 mg/dL from PET/CT protocols. Additionally, to minimize CT effective doses and adhere to the ALARA principle, reducing tube-current modulation is advised, as it significantly impacts DLP values and the overall effective dose in PET/CT procedures.
期刊介绍：
Radiation Physics and Chemistry is a multidisciplinary journal that provides a medium for publication of substantial and original papers, reviews, and short communications which focus on research and developments involving ionizing radiation in radiation physics, radiation chemistry and radiation processing.
The journal aims to publish papers with significance to an international audience, containing substantial novelty and scientific impact. The Editors reserve the rights to reject, with or without external review, papers that do not meet these criteria. This could include papers that are very similar to previous publications, only with changed target substrates, employed materials, analyzed sites and experimental methods, report results without presenting new insights and/or hypothesis testing, or do not focus on the radiation effects.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
